Laurus Labs has said it has received the license from Defence Research and Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug 2-Deoxy-D-Glucose (2DG). 2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country, Laurus Labs said in a regulatory filing.

“Laurus Labs has already applied with the Central Drugs Standard Control Organisation (CDSCO) for emergency use authorization (EUA) for 2DG,” it added.

• NLC India To Start Mining In Machhakata Coal Block
• P N Gadgil Jewellers Ltd IPO GMP, Issue Date, Key Dates & Financials
• European Stocks Sink Ahead of U.S. Payrolls’ Report
• Coal Ministry Allocates Orders for 3 Commercial Mines, Rs 4,500 crore Investment Potential
• SEBI To Tighten F&O Rules Despite Investor Pushback: Report

On June 28, pharma major Dr Reddy’s announced the commercial launch of 2DG at a maximum retail price of Rs 990 per sachet. Shares of Laurus Labs were trading at Rs 674.20 per scrip on BSE, up 1.08 per cent from the previous close.